Age interacts with the expression of steroid and HER-2 receptors in operable invasive breast cancer

Breast Cancer Research and Treatment

Volumn 110, Issue 1, 2008, Pages 153-159

  Neven, P ^a   Van Calster, B ^b   Van Den Bempt, I ^a   Van Huffel, S ^b   Van Belle, V ^b   Hendrickx, W ^a   Decock, J ^a   Wildiers, H ^a   Paridaens, R ^a   Amant, F ^a   Leunen, K ^a   Berteloot, P ^a   Timmerman, D ^a   Van Limbergen, E ^a   Weltens, C ^a   Van Den Bogaert, W ^a   Smeets, A ^a   Vergote, I ^a   Christiaens, M R ^a   Drijkoningen, M ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

Breast cancer; Hormone receptors; Human epidermal growth factor receptor 2; Interaction

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; STEROID RECEPTOR;

ADULT; AGE DETERMINATION; AGED; ARTICLE; BREAST CANCER; CANCER CELL; CONFIDENCE INTERVAL; CONTROLLED STUDY; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RISK;

ADULT; AGED; AGING; BREAST NEOPLASMS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE;

EID: 44849141664     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10549-007-9687-4     Document Type: Article

References (31)

1. Clark GM, Osborne CK, McGuire WL (1984) Correlations between estrogen receptor, progesterone receptor, and patient characteristics in human breast cancer. J Clin Oncol 2:1102-1109
2. Taucher S, Rudas M, Mader RM et al (2003) Do we need HER-2/neu testing for all patients with primary breast carcinoma? Cancer 98:2547-2553
3. Osborne CK, Schiff R (2003) Growth factor receptor cross-talk with estrogen receptor as a mechanism for tamoxifen resistance in breast cancer. Breast 12:362-367. Review
4. Zeillinger R, Kury F, Czerwenka K et al (1989) HER-2 amplification, steroid receptors and epidermal growth factor receptor in primary breast cancer. Oncogene 4:109-114
5. Marsigliante S, Muscella A, Ciardo V et al (1993) Enzyme-linked immunosorbent assay of HER-2/neu gene product (p185) in breast cancer: its correlation with sex steroid receptors, cathepsin D and histologic grades. Cancer Lett 75:195-206
6. Konecny G, Pauletti G, Pegram M et al (2003) Quantitative association between HER-2/neu and steroid hormone receptors in hormone receptor positive primary breast cancer. J Natl Cancer Inst 95:142-153
7. Huang HJ, Neven P, Drijkoningen M et al (2005) Association between tumour characteristics and HER-2/neu by immunohistochemistry in 1362 women with primary operable breast cancer. J Clin Pathol 58:611-616
8. Arpino G, Weiss H, Lee AV et al (2005) Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance. J Natl Cancer Inst 97:1254-1261
9. Huang HJ, Neven P, Drijkoningen M et al (2005) Association between HER-2/neu and the progesterone receptor in oestrogen-dependent breast cancer is age-related. Breast Cancer Res Treat 91:81-87
10. Benz CC, Scott GK, Sarup JC et al (1993) Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu. Breast Cancer Res Treat 24:85-95
11. Pietras RJ, Arboleda J, Reese DM et al (1995) HER-2 tyrosine kinase pathway targets estrogen receptor and promotes hormone-independent growth in human breast cancer cells. Oncogene 10:2435-2446
12. De Placido S, De Laurentiis M, Carlomagno C et al (2003) Twenty-year results of the Naples GUN randomized trial: predictive factors of adjuvant tamoxifen efficacy in early breast cancer. Clin Cancer Res 9:1039-1046
13. Shou J, Massarweh S, Osborne CK et al (2004) Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer. J Natl Cancer Inst 96:926-935
14. Love RR, Duc NB, Havighurst TC et al (2003) HER-2/neu overexpression and response to oophorectomy plus tamoxifen adjuvant therapy in estrogen receptor-positive premenopausal women with operable breast cancer. J Clin Oncol 21:453-457
15. Ellis MJ, Coop A, Singh B et al (2001) Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial. J Clin Oncol 19:3808-3816
16. Dowsett M, Allred DC (2006) Relationship between quantitative ER and PgR expression and HER2 status with recurrence in the ATAC trial. Breast Cancer Res Treat 100:S21 (Abstr 48)
17. Viale G, Regan M, Dell'Orto P et al (2006) Central review of ER, PgR and HER-2 in BIG 1-98 evaluating letrozole versus tamoxifen as adjuvant endocrine therapy for postmenopausal women with receptor-positive breast cancer. Breast Cancer Res Treat 100:S21 (Abstr 39)
18. Lee AV, Weiss H, Cui X, Osborne CK, Arpino G, Schiff R (2006) Biology of progesterone receptor loss in breast cancer and its implications for endocrine therapy. J Clin Oncol 24:2595-2597
19. Hastie TJ, Tibshirani RJ (1990) Generalized additive models. Chapman & Hall/CRC, New York
20. Hosmer DW, Lemeshow S (2000). Applied logistic regression, 2nd edn. Wiley, New York
21. Rosen PP, Lesser ML, Senie RT, Duthie K (1982) Epidemiology of breast carcinoma IV: age and histologic tumor type. J Surg Oncol 19:44-51
22. Wenger CR, Beardslee S, Owens MA et al (1993) DNA ploidy, S-phase, and steroid receptors in more than 127,000 breast cancer patients. Breast Cancer Res Treat 28:9-20
23. Osborne CK (1998) Steroid hormone receptors in breast cancer management. Breast Cancer Res Treat 51:227-238
24. Anderson WF, Chu KC, Chatterjee N, Brawley O, Brinton LA (2001) Tumour variants by hormone receptor expression in white patients with node-negative breast cancer from the surveillance, epidemiology, and end results database. J Clin Oncol 19:18-27
25. Eppenberger-Castori S, Moore DH, Thor AD et al (2002) Age-associated biomarker profiles of human breast cancer. Int J Biochem Cell Biol 34:1318-1330
26. Maru D, Middleton LP, Wang S, Valero V, Sahin A (2005) HER-2/neu and p53 overexpression as biomarkers of breast carcinoma in women age 30 years and younger. Cancer 103:900-905
27. Prati R, Apple SK, He J, Gornbein JA, Chang HR (2005) Histopathologic characteristics predicting HER-2/neu amplification. Breast J 11:433-439
28. Colleoni M, Rotmensz N, Robertson C et al (2002) Very young women (<35 years) with operable breast cancer: features of disease at presentation. Ann Oncol 13:273-279
29. Perou CM, Sorlie T, Eisen MB et al (2000) Molecular portraits of human breast tumours. Nature 406:747-752
30. Carey LA, Perou CM, Livasy CA et al (2006) Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. J Am Med Assoc 295:2492-2502
31. Peiro G, Adrover E, Aranda FI, Peiro FM, Niveiro M, Sanchez-Paya J (2007) Prognostic implications of HER-2 status in steroid receptor-positive, lymph node-negative breast carcinoma. Am J Clin Pathol 127:780-786